II-Type Intervertebral Spacer

K180228 · Paonan Biotech Co., Ltd. · MAX · Jan 11, 2019 · Orthopedic

Device Facts

• Record ID: K180228
• Device Name: II-Type Intervertebral Spacer
• Applicant: Paonan Biotech Co., Ltd.
• Product Code: MAX · Orthopedic
• Decision Date: Jan 11, 2019
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 888.3080
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The II-Type Intervertebral Spacer is indicated for intervertebral body fusion procedures in skeletally mature patients with degenerative disc disease (DDD) at one or two contiguous levels from L2-S1. This device is to be used with autograft bone and/or allograft bone comprised of cancellous and/or corticocancellous bone graft. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient history and radiographic studies. These patients may also have up to Grade 1 spondylolisthesis or retrolisthesis at the involved level(s). Patients should have at least six months of non-operative treatment prior to treatment with an intervertebral cage. The II-Type Intervertebral Spacer is to be implanted via a direct posterior approach. These devices are intended to be used with supplemental fixation instrumentation, which has been cleared by the FDA for use in the lumbar spine.

Device Story

Intervertebral spacer device; PEEK cage with tantalum markers; implanted via direct posterior approach; used in lumbar interbody fusion surgeries to restore disc height and lordosis; facilitates nerve-root decompression; packed with autograft or allograft bone; requires supplemental fixation instrumentation; used by surgeons in clinical settings; provides structural support during fusion; enables radiographic monitoring of fusion progress via radiolucent material and metal markers.

Clinical Evidence

No clinical data; bench testing only. Mechanical testing performed per ASTM F2077-11 (static/dynamic axial compression, static torsion, static compression-shear) and ASTM F2267-04 (subsidence) using worst-case constructs.

Technological Characteristics

Material: Poly Ether Ketone (PEEK) with Tantalum (Ta) markers. Form factor: Intervertebral cage of various widths/heights. Principle: Mechanical support for interbody arthrodesis. Standards: ASTM F2077-11, ASTM F2267-04. Connectivity: None. Software: None.

Indications for Use

Indicated for skeletally mature patients with degenerative disc disease (DDD) at one or two contiguous levels from L2-S1, including those with up to Grade 1 spondylolisthesis or retrolisthesis, who have failed at least six months of non-operative treatment.

Regulatory Classification

Identification

An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.

Special Controls

*Classification.* (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval. (c) *Date premarket approval application (PMA) or notice of product development protocol (PDP) is required.* Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.

Predicate Devices

• Lumbar I/F Cage (P960025)
• Capstone Spinal System (K073291)
• FORZA Spacer System (K103111)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logos of the Department of Health & Human Services and the U.S. Food & Drug Administration (FDA). The Department of Health & Human Services logo is on the left, featuring a stylized human figure. To the right is the FDA logo, with the letters 'FDA' in a blue square, followed by 'U.S. FOOD & DRUG ADMINISTRATION' in blue text.

Paonan Biotech Co., Ltd. Vivi Tsai Regulation Affair 3F, No. 50, Lane 258, Rueiguang Rd. Neihu District, Taipei, 11491 Taiwan, R.O.C.

Re: K180228

Trade/Device Name: II-Type Intervertebral Spacer Regulation Number: 21 CFR 888.3080 Regulation Name: Intervertebral Body Fusion Device Regulatory Class: Class II Product Code: MAX Dated: December 4, 2018 Received: December 10, 2018

Dear Vivi Tsai:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You mav, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be avare that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's

January 11, 2019

{1}------------------------------------------------

requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.html; good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely.

# Katherine D. Kavlock -S

for

Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

## Indications for Use

510(k) Number (if known) K180228

Device Name II-Type Intervertebral Spacer

Indications for Use (Describe)

The II-Type Intervertebral Spacer is intervertebral body fusion procedures in skeletally mature patients with degenerative disc disease (DDD) at one or two contiguous levels from L2-S1. This device is to be used with autograft bone and/or allograft bone comprised of cancellous bone graft. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient history and radiographic studies. These patients may also have up to Grade 1 spondylolisthesis or retrolisthesis at the involved level(s). Patients should have at least six months of non-operative treatment prior to treatment with an intervertebral cage. The II-Type Intervertebral Spacer is to be implanted via a direct posterior approach. These devices are intended to be used with supplemental fixation instrumentation, which has been cleared by the FDA for use in the lumbar spine.

Type of Use (*Select one or both, as applicable*)

| <span style="font-size:12px"><b></b></span> | Prescription Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart C) |
|---------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <span style="font-size:12px"><b></b></span> | <div style="display:inline-block;vertical-align:middle"><svg height="16" width="16"><path d="M2 2h12v12H2V2z" fill="none" stroke="black" stroke-width="1"></path></svg><svg height="16" width="16"><path d="M4 4h8v8H4V4z" fill="black" stroke="black" stroke-width="2"></path></svg></div> | <div style="display:inline-block;vertical-align:middle"><svg height="16" width="16"><path d="M2 2h12v12H2V2z" fill="none" stroke="black" stroke-width="1"></path></svg></div> |

CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW!*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.qov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2020 See PRA Statement below.

{3}------------------------------------------------

## K180228

## 510(k) Summary

This summary regarding 510(k) safety and effectiveness information is being submitted in accordance with the requirements of 21CFR 807.92.

| Submitter Information: | Paonan Biotech. Co., Ltd.<br>3F, No. 50, Lane. 258, Rueiguang<br>Rd., Neihu District, Taipei City, Taiwan, R.O.C. | |
|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| Contact Person: | Vivi Tsai<br>TEL: [phone]<br>FAX: [phone]<br>Email: [e-mail] | |
| Date Prepared: | Nov. 15th, 2018 | |
| Trade Name: | II-Type Intervertebral Spacer | |
| Common Name: | Intervertebral Spacer | |
| Classification Name: | Intervertebral Fusion Device With Bone Graft<br>(21 CFR 888.3080) | |
| Device Class: | Class II | |
| Panel: | Orthopedic | |
| Product Code: | MAX | |
| Predicate Devices: | Primary predicate device:<br>Lumbar I/F Cage<br>(P960025)<br>Additional predicates:<br>Capstone Spinal System (K073291)<br>FORZA Spacer System (K103111) | |

### Device Description:

II-Type Intervertebral Spacer consists of PEEK cages of various widths and heights, which include Ta markers, which can be inserted between two lumbar or lumbosacral vertebral bodies to give support and correction during lumbar interbody fusion surgeries. The hollow geometry of the implants allows them to be packed with autograft bone and/or allograft bone comprised of cancellous and/or corticocancellous bone graft.

#### Intended Use:

The II-Type Intervertebral Spacer is indicated for intervertebral body fusion procedures in skeletally mature patients with degenerative disc disease (DDD) at one or two contiguous levels from L2-S1. This device is to be used with autograft bone and/or allograft bone comprised of cancellous and/or

{4}------------------------------------------------

corticocancellous bone graft. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient history and radiographic studies. These patients may also have up to Grade 1 spondylolisthesis or retrolisthesis at the involved level(s). Patients should have at least six months of non-operative treatment prior to treatment with an intervertebral cage. The II-Type Intervertebral Spacer is to be implanted via a direct posterior approach. These devices are intended to be used with supplemental fixation instrumentation, which has been cleared by the FDA for use in the lumbar spine.

## Technological Characteristics:

The II-Type Intervertebral Spacer implanted via posterior approach are intended to facilitate interbody arthrodesis. These cages allow restoration of the disc height and natural lordosis. Nerve-root decompression is also achieved by opening the neural foramen.

The II-Type Intervertebral Spacer are entirely made of Poly Ether Ketone (PEEK), a biocompatible material with modulus characteristics similar to vertebral bone. They are fully radiolucent, which enables optimum follow-up with diagnostic imaging, as the interbody fusion progresses. Two metal wires at the opposite ends of the cage allow radiological confirmation of the cage position post operatively.

## Non-Clinical Performance Data:

Paonan has submitted data from testing performed in compliance with ASTM F 2077-11 including static and dynamic axial compression test, static torsion test, static compression-shear test, and ASTM F 2267-04 subsidence test using samples each of a worst case construct demonstrate that the II-Type Intervertebral Spacer is substantially equivalent to legally marketed lumbar interbody fusion and is therefore appropriate for use in lumbar interbody fusion as described in the indication above.

## Clinical Performance Data:

Clinical testing was not required for this submission.

## Conclusion of Substantial Equivalence:

The II-Type Intervertebral Spacer has been demonstrated to be substantially equivalent to predicate system with respect to technical characteristics, performance, and intended use. The information provided within this premarket notification supports substantial equivalence of the subject device to the predicate device